Keyphrases
Netherlands
100%
Health Impact
100%
Budget Impact
100%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
100%
Dutch
50%
Type 2 Diabetes Mellitus (T2DM)
50%
Clinical Practice Guidelines
30%
Economic Impact
20%
Disease-related
20%
Cardiovascular Disease
20%
Quality-adjusted Life Years
20%
Health Care Costs
20%
Type 2 Diabetic Patients
20%
Life-years Gained
20%
Chronic Kidney Disease
20%
Drug Class
20%
Glucose-lowering Drugs
20%
Kidney Disease Progression
20%
Health Benefits
10%
Cardiovascular Risk
10%
Societal Perspective
10%
Loss Cost
10%
Population at Risk
10%
Patient Demographics
10%
Cost Savings
10%
Clinical Trials
10%
Management Options
10%
Direct Medical Costs
10%
Treatment Setting
10%
Prevalence Rate
10%
Patient Risk
10%
Disease Progression
10%
Disease Prevalence
10%
Updated Guidelines
10%
Renal Outcome
10%
Treatment Costs
10%
Cardiovascular Events
10%
Renal Disease
10%
Number of Inhabitants
10%
Clinical Events
10%
Cardiovascular Disease Events
10%
Cardiovascular Outcomes
10%
Health Loss
10%
Disease Event
10%
New Guidelines
10%
Disutility
10%
Patients at Risk
10%
Adverse Event Rates
10%
Diabetes Mellitus Treatment
10%
Diabetes Mellitus Management
10%
Event Rate
10%
Pharmacology, Toxicology and Pharmaceutical Science
Sodium Glucose Cotransporter 2 Inhibitor
100%
Non Insulin Dependent Diabetes Mellitus
70%
Cardiovascular Disease
40%
Chronic Kidney Failure
30%
Kidney Disease
20%
Prevalence
20%
Disease
10%
Adverse Event
10%
Clinical Trial
10%